GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase (ACC) Inhibitor, Reduces Plasma Acylcarnitines in Patients with Nonalcoholic Steatohepatitis (NASH)

被引：0
|
作者：
Charlton, Michael R. [1 ]
Lai, Michelle [2 ,3 ]
Noureddin, Mazen [4 ]
Tarrant, Jacqueline M. [5 ]
Wang, Lulu [5 ]
Tuan Nguyen [5 ]
McColgan, Bryan John [5 ]
Chung, Chuhan [5 ]
Patterson, Scott D. [5 ]
Myers, Robert P. [5 ]
Mantry, Parvez [6 ]
Ruane, Peter J. [7 ]
Loomba, Rohit [8 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Harvard Med Sch, Boston, MA USA
[4] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
[6] Methodist Dallas Med Ctr, Liver Inst & Intervent Radiol, Dallas, TX USA
[7] Ruane Clin Res, Los Angeles, CA USA
[8] Univ Calif San Diego, Div Gastroenterol, NAFLD Res Ctr, San Diego, CA 92103 USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1741
引用
收藏
页码：992A / 993A
页数：2
相关论文
共 37 条
  • [21] A PHASE 1 MASS BALANCE STUDY OF FIRSOCOSTAT, A LIVER-TARGETED ACETYL-COA CARBOXYLASE INHIBITOR.
    Hsueh, C.
    Qin, A.
    West, S.
    Chung, C.
    Othman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S24 - S24
  • [22] A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH
    Bates, Jamie
    Hollenback, David
    Liu, Kathy
    Wang, Ting
    Wong, Kari E.
    Ray, Adrian S.
    Breckenridge, David
    HEPATOLOGY, 2017, 66 : 1084A - 1084A
  • [23] Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH
    Lawitz, E.
    Herring, R., Jr.
    Younes, Z. H.
    Gane, E.
    Ruane, P.
    Schall, R. A.
    Jia, C.
    Xu, R.
    Mccolgan, B.
    Djedjos, S.
    Subramanian, M.
    Mchutchison, J. G.
    Myers, R.
    Middleton, M.
    Li, K.
    Hellerstein, M.
    Kwo, P.
    Noureddin, M.
    Harrison, S.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S57 - S57
  • [24] PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH
    Lawitz, Eric
    Herring, Robert
    Younes, Ziad H.
    Gane, Edward
    Ruane, Peter J.
    Aguilar, Raul
    Jia, Catherine
    Xu, Ren
    McColgan, Bryan
    Oberle, Corinna
    Djedjos, C. Stephen
    Subramanian, G. Mani
    McHutchison, John G.
    Myers, Robert P.
    Middleton, Michael
    Li, Kelvin
    Hellerstein, Marc
    Kwo, Paul
    Noureddin, Mazen
    Harrison, Stephen A.
    SWISS MEDICAL WEEKLY, 2018, 148 : 24S - 24S
  • [25] Proof-of-concept study of an apoptosis-signal regulating kinase inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in non-alcoholic steatohepatitis
    Gane, E.
    Lawitz, E.
    Herring, R.
    Younes, Z. H.
    Ruane, P. J.
    Aguilar, R.
    Jia, C.
    Xu, R.
    Mccolgan, B.
    Djedjos, S.
    Subramanian, M.
    Mchutchison, J. G.
    Myers, R. P.
    Middleton, M.
    Li, K.
    Hellerstein, M.
    Kwo, P.
    Noureddin, M.
    Harrison, S. A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 57 - 58
  • [26] PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK-1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH
    Lawitz, Eric
    Herring, Robert
    Younes, Ziad H.
    Gane, Edward
    Ruane, Peter J.
    Aguilar, Raul
    Jia, Catherine
    Xu, Ren
    McColgan, Bryan J.
    Natha, Macky
    Djedjos, C. Stephen
    Subramanian, Mani
    McHutchison, John
    Myers, Robert P.
    Middleton, Michael S.
    Li, Kelvin
    Hellerstein, Marc
    Kwo, Paul Yien
    Noureddin, Mazen
    Harrison, Stephen A.
    GASTROENTEROLOGY, 2018, 154 (06) : S1166 - S1167
  • [27] Evaluation of Cytochrome P450-and Transporter-Mediated Drug-Drug Interactions with the Acetyl-CoA Carboxylase Inhibitor GS-0976 and Phenotypic Probe Substrates and Inhibitors
    Weber, Elijah
    Nelson, Cara
    Yue, Mun Sang
    Vesterdahl, Adrianne
    McColgan, Bryan John
    Qin, Ann R.
    Kirby, Brian
    HEPATOLOGY, 2018, 68 : 988A - 989A
  • [28] Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans
    Ryder, Tim F.
    Bergman, Arthur
    King-Ahmad, Amanda
    Amin, Neeta B.
    Lall, Manjinder S.
    Ballard, T. Eric
    Kalgutkar, Amit S.
    XENOBIOTICA, 2022, 52 (03) : 240 - 253
  • [29] Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver Targeted ACC Inhibitor, on De Novo Lipogenesis
    Kirby, Brian
    Lutz, Justin D.
    Garrison, Kimberly L.
    Datyani, Vinay
    Vesterdahl, Adrianne
    Yue, Mun Sang
    Qin, Ann R.
    Myers, Robert P.
    Kearney, Brian P.
    Mathias, Anita
    HEPATOLOGY, 2018, 68 : 971A - 971A
  • [30] Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model
    Tamura, Yumiko Okano
    Sugama, Jun
    Iwasaki, Shinji
    Sasaki, Masako
    Yasuno, Hironobu
    Aoyama, Kazunobu
    Watanabe, Masanori
    Erion, Derek M.
    Yashiro, Hiroaki
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2021, 379 (03): : 280 - 289
1234